KHTRF (Knight Therapeutics) Cyclically Adjusted Revenue per Share: $1.49 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KHTRF Knight Therapeutics Inc KHTRF
72 GF Score
Price $6.91
GF Value $6.16
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Knight Therapeutics Cyclically Adjusted Revenue per Share?

Knight Therapeutics KHTRF +0.17% 72 Cyclically Adjusted Revenue per Share is $1.49 as of Mar. 2026. GuruFocus rates KHTRF with a GF Score™ of 72/100 and a GF Value™ of $6.16 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Knight Therapeutics's adjusted revenue per share for the three months ended in Mar. 2026 was $1.094. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.49 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Knight Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 36.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-27), Knight Therapeutics's current stock price is $6.906. Knight Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $1.49. Knight Therapeutics's Cyclically Adjusted PS Ratio of today is 4.63.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Knight Therapeutics was 5.27. The lowest was 3.05. And the median was 4.03.


Knight Therapeutics  (OTCPK:KHTRF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Knight Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=6.906/1.49
=4.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Knight Therapeutics was 5.27. The lowest was 3.05. And the median was 4.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Knight Therapeutics Cyclically Adjusted Revenue per Share Related Terms


Knight Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Knight Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Knight Therapeutics Cyclically Adjusted Revenue per Share Chart

Knight Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.83 0.96 1.37

Knight Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.04 1.19 1.33 1.37 1.49

KHTRF vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Cyclically Adjusted PS Ratio falls into.


KHTRF
72GF Score
Knight Therapeutics Inc KHTRF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Knight Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Knight Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.094/132.2623*132.2623
=1.094

Current CPI (Mar. 2026) = 132.2623.

Knight Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.008 102.002 0.010
201609 0.011 101.765 0.014
201612 0.010 101.449 0.013
201703 0.009 102.634 0.012
201706 0.013 103.029 0.017
201709 0.011 103.345 0.014
201712 0.014 103.345 0.018
201803 0.017 105.004 0.021
201806 0.012 105.557 0.015
201809 0.017 105.636 0.021
201812 0.020 105.399 0.025
201903 0.015 106.979 0.019
201906 0.017 107.690 0.021
201909 0.022 107.611 0.027
201912 0.208 107.769 0.255
202003 0.242 107.927 0.297
202006 0.299 108.401 0.365
202009 0.261 108.164 0.319
202012 0.331 108.559 0.403
202103 0.284 110.298 0.341
202106 0.427 111.720 0.506
202109 0.470 112.905 0.551
202112 0.379 113.774 0.441
202203 0.430 117.646 0.483
202206 0.514 120.806 0.563
202209 0.473 120.648 0.519
202212 0.533 120.964 0.583
202303 0.541 122.702 0.583
202306 0.623 124.203 0.663
202309 0.565 125.230 0.597
202312 0.533 125.072 0.564
202403 0.632 126.258 0.662
202406 0.688 127.522 0.714
202409 0.673 127.285 0.699
202412 0.666 127.364 0.692
202503 0.613 129.181 0.628
202506 0.788 129.892 0.802
202509 0.882 130.287 0.895
202512 0.971 130.366 0.985
202603 1.094 132.262 1.094

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $1.49 mean?
Knight Therapeutics (KHTRF) has a Cyclically Adjusted Revenue per Share of $1.49 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Knight Therapeutics and its competitors.
Is Knight Therapeutics' Cyclically Adjusted Revenue per Share too high?
Knight Therapeutics' current Cyclically Adjusted Revenue per Share is $1.49. Overall, Knight Therapeutics has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Cyclically Adjusted Revenue per Share compare to ZTS?
Knight Therapeutics' Cyclically Adjusted Revenue per Share of $1.49 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Knight Therapeutics and its competitors. Knight Therapeutics's current Cyclically Adjusted Revenue per Share is $1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Knight Therapeutics (KHTRF) is currently considered Modestly Overvalued. The stock's GF Value™ is $6.16, compared to a current price of $6.91 — trading 12.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $1.49. Knight Therapeutics' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Knight Therapeutics (KHTRF), the current Cyclically Adjusted Revenue per Share is $1.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Knight Therapeutics (KHTRF) Overvalued in 2026?

Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued. The current stock price of $6.91 is trading 12.1% above its estimated GF Value™ of $6.16. GuruFocus considers Knight Therapeutics to be Modestly Overvalued.

Key valuation signals for KHTRF:

  • Cyclically Adjusted Revenue per Share: $1.49
  • GF Value™: $6.16 vs. price of $6.91 (12.1% above fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the KHTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Knight Therapeutics Business Description

Other Exchanges GUD:Canada
Address 100 Alexis Nihon Boulevard, Suite 600, Saint-Laurent, QC, CAN, H4M 2P2
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
72GF Score

Get the complete analysis for KHTRF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.91
Price
$6.16
GF Value